TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-1.41%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.59B
AUM Growth
+$2.59B
(-7.3%)
Cap. Flow
-$80.8M
Cap. Flow
% of AUM
-3.12%
Top 10 Holdings %
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
46
Closed
8
Top Buys
| 1 |
Amgen
AMGN
|
$42.1M |
| 2 |
AbbVie
ABBV
|
$23.4M |
| 3 |
Bristol-Myers Squibb
BMY
|
$21.4M |
| 4 |
CELG
Celgene Corp
CELG
|
$13.2M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$11.2M |
Top Sells
| 1 |
Abbott
ABT
|
$25.8M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$23.6M |
| 3 |
AGN
Allergan plc
AGN
|
$21.4M |
| 4 |
Gilead Sciences
GILD
|
$20.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$18.4M |
Sector Composition
| 1 | Healthcare | 92.75% |
| 2 | Real Estate | 2.87% |
| 3 | Financials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Exelixis
EXEL
$9.95B
| $11.8M | 0.46% |
388,822
| – | – |
|
|
SAGE
52
DELISTED
Sage Therapeutics
SAGE
| $11.2M | 0.43% |
+67,815
| New | +$11.2M |
|
53
Elevance Health
ELV
$72.4B
| $10.1M | 0.39% |
44,918
| – | – |
|
54
Zimmer Biomet
ZBH
$20.8B
| $9.69M | 0.37% |
82,709
+12,875
| +18% | +$1.51M |
|
55
Charles River Laboratories
CRL
$7.99B
| $9.39M | 0.36% |
85,804
-41,296
| -32% | -$4.52M |
|
56
Merus
MRUS
$5.04B
| $9.28M | 0.36% |
479,150
| – | – |
|
|
LTC
57
LTC Properties
LTC
$1.67B
| $9.13M | 0.35% |
209,673
+73,461
| +54% | +$3.2M |
|
|
CLLS
58
Cellectis
CLLS
$260M
| $9.04M | 0.35% |
310,250
| – | – |
|
59
Acadia Healthcare
ACHC
$2.15B
| $8.89M | 0.34% |
272,400
| – | – |
|
60
Amicus Therapeutics
FOLD
$2.42B
| $8.71M | 0.34% |
604,920
+329,426
| +120% | +$4.74M |
|
|
AET
61
DELISTED
Aetna Inc
AET
| $8.58M | 0.33% |
+47,566
| New | +$8.58M |
|
|
BLUE
62
DELISTED
bluebird bio
BLUE
| $8.39M | 0.32% |
3,636
+2,611
| +255% | +$6.02M |
|
63
Alkermes
ALKS
$4.95B
| $7.89M | 0.3% |
+144,072
| New | +$7.89M |
|
|
AVXS
64
DELISTED
AveXis, Inc. Common Stock
AVXS
| $7.79M | 0.3% |
70,347
+60,347
| +603% | +$6.68M |
|
65
Sanofi
SNY
$122B
| $7.74M | 0.3% |
179,900
| – | – |
|
|
DERM
66
DELISTED
Dermira, Inc.
DERM
| $7.47M | 0.29% |
268,500
-128,400
| -32% | -$3.57M |
|
67
Acadia Pharmaceuticals
ACAD
$4.34B
| $7.4M | 0.29% |
+245,885
| New | +$7.4M |
|
68
Edwards Lifesciences
EW
$47.7B
| $7.34M | 0.28% |
195,300
-96,900
| -33% | -$3.64M |
|
|
ENDP
69
DELISTED
Endo International plc
ENDP
| $7.09M | 0.27% |
914,548
| – | – |
|
70
Ultragenyx Pharmaceutical
RARE
$3.04B
| $6.89M | 0.27% |
148,558
| – | – |
|
|
NUVA
71
DELISTED
NuVasive, Inc.
NUVA
| $6.87M | 0.26% |
117,437
-44,139
| -27% | -$2.58M |
|
|
SNR
72
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
| $6.68M | 0.26% |
883,919
+315,922
| +56% | +$2.39M |
|
73
Boston Scientific
BSX
$159B
| $6.56M | 0.25% |
+264,600
| New | +$6.56M |
|
74
uniQure
QURE
$954M
| $6.52M | 0.25% |
332,850
+91,829
| +38% | +$1.8M |
|
75
Ionis Pharmaceuticals
IONS
$9.64B
| $6.49M | 0.25% |
+128,930
| New | +$6.49M |
|